Please assess the completion status of the following clinical trial:

Trial Title: Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Age ≥ 18 years~* Histological or cytological evidence of lung cancer~* Presence of bone metastases documented on bone X-ray, bone ECT, CT scan or MRI scan~* Mean pain score ≥ 4 during 3-day baseline period on the WORSE pain scale of the VAS~* Patients must be on a stable dose of analgesics over the 3-day baseline period (maximum 15% variation is allowed)~* ECOG Performance status of 0-3 (patients with PS of 3 must have their score based on bone pain, not underlying neoplastic disease)~* Adequate renal function: creatinine clearance ≥ 50 ml/min (cockroft formula) and serum creatinine ≤ 2.0mg/dl (168 µmol/L); ALT or AST within 2 times the upper limit of the normal range~Exclusion Criteria:~* Patients with an uncontrolled infection~* Hypocalcemia~* Patients who have received a bisphosphonate within 3 weeks of the start of the Baseline period or who are currently receiving another bisphosphonate~* Patients with known hypersensitivity to any of the components of ibandronic acid~* Patients who are pregnant or lactating~* Radiotherapy to bone within the 28 days prior inclusion or during the trial duration~* Patient who are currently treated with any other investigational therapy or have received it within 30 days of the first schedule day of dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Intravenous infusion of either 6mg Bondronat on three consecutive days
- B (Type: ACTIVE_COMPARATOR): Intravenous infusion of 6mg Bondronat on one day

Based on this trial design, predict the completion outcome and termination type (if applicable).